Join us June 13 for a Journal Club event!
 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌


Problems viewing this email?

View Message In Browser
<[link removed]>

Sunday, June 11, 2023 | The Latest Research, Commentary, And News From
Health Affairs

Dear John,

To celebrate Health Affairs Insider's first anniversary, new Insider or
Unlimited members can enjoy $40 off to celebrate Health Affairs
Insider's first anniversary!

Use discount code InsiderAtOne
<[link removed]>.

Medicaid, Drug Pricing, Aging & More

This week, we released a new issue!

The June issue of Health Affairs
<[link removed]>
explores a wide range of topics, including children's Medicaid
coverage, competition in the biosimilars market, sites of care for
people with Alzheimer's disease, and more.

We are pleased to include for the first time the official projections of
nonelderly
<[link removed]>health
insurance coverage for 2023-33
<[link removed]>
prepared by the Congressional Budget Office Coverage Team of Caroline
Hanson and colleagues.

One of the areas of focus in this issue was drug pricing.

Through the Medicaid Drug Rebate Program, state Medicaid programs
receive mandatory rebates when prices rise faster than inflation.

Congress expanded that program in 2017 to include generic drugs.

Benjamin Rome and coauthors find that between 2017 and
<[link removed]>2020
<[link removed]>,
inflationary rebates "offset an estimated 2-12 percent of the $54
billion total Medicaid generic drug spending."

Alice Chen and coauthors compare
<[link removed]>prices
and market-share dominance
<[link removed]>
of the cancer drug trastuzumab (Herceptin) and five biosimilars.

They find that after the introduction of biosimilars in 2019- 20,
Herceptin accounted for 45.3 percent of Medicare trastuzumab claims,
whereas Kanjinti (a biosimilar) accounted for 39.6 percent of claims.

Check out the table of contents
<[link removed]>
to take a look at all of the articles in this month's edition.

Read The Issue
<[link removed]>


Health Affairs Branded Post:

The Healing Effects of Social Connection and Community
<[link removed]>

Sponsored by UnitedHealthcare Community & State
<[link removed]>

 

[link removed]


 

[link removed]


LGBTQ+ Health Care Policies: Two Steps Forward, Two Steps Backward?
<[link removed]>

In honor of Pride Month, Health Affairs' Kathleen Haddad and Michael
Gerber discuss the state of health policy related to the LBGTQ+
community. They discuss the impact of state policies on the community,
the burgeoning data on gender, and more.

Kelsey Owsley on 340B's Effect on Oncology Services
<[link removed]>

Health Affairs' Alan Weil interviews Kelsey Owsley from the University
of Arkansas for Medical Sciences on her new paper assessing whether the
340B drug pricing program leads to increase in oncology services in
rural hospitals.

 

[link removed]


 

Medicare Drug Price Negotiation: Few Drugs, Big Impact
<[link removed]>

Sarosh Nagar et al.

ChatGPT and Health Care: Implications for Interoperability and Fairness
<[link removed]>

Niam Yaraghi

A Victory for Medicaid Beneficiaries In Supreme Court's Talevski
Decision
<[link removed]>

Sara Rosenbaum et al.

To Treat Residents with OUD, Nursing Facilities Must Improve Practices
and Reduce Stigma
<[link removed]>

Dina Besirevic et al.

Policy Design Tools For Achieving Equity Through Value-Based Payment,
Part 1
<[link removed]>
Amol Navanthe et al.

Policy Design Tools for Achieving Equity Through Value-Based Payment,
Part 2
<[link removed]>
Amol Navanthe et al.

An Early Look At What Drove 2022's Health Care Spending Slowdown
<[link removed]>
Corwin Rhyan and George Miller

Current and Future Legal Attacks Against The Medicare Drug Price
Negotiation Program
<[link removed]>
Zachary Baron and Andrew Twinamatsiko

The IRA's Request For Product-Specific R&D Cost Information:
Short-Sighted and Irrelevant
<[link removed]>
Louis Garrison, Jr. and Adrian Towse

By Leaving 'Therapeutic Alternatives' Undefined, CMS Tilts the Playing
Field of Drug Price Negotiations
<[link removed]>
Richard Hughes IV et al.

[link removed]


 

About Health Affairs

Health Affairs is the leading peer-reviewed journal
<[link removed]> at the
intersection of health, health care, and policy. Published monthly by
Project HOPE, the journal is available in print and online.
Late-breaking content is also found through healthaffairs.org
<[link removed]>, Health Affairs Today
<[link removed]>, and Health Affairs Sunday
Update <[link removed]>.  

Project HOPE <[link removed]> is a global health and
humanitarian relief organization that places power in the hands of local
health care workers to save lives across the globe. Project HOPE has
published Health Affairs since 1981.

Copyright © Project HOPE: The People-to-People Health Foundation, Inc.

Health Affairs, 1220 19th Street, NW, Suite 800, Washington, DC 20036, United States

Privacy Policy <[link removed]>

To unsubscribe from this email, update your email preferences here
<[link removed]>.

[link removed]

 

[link removed]

 

[link removed]

 

[link removed]

 

mailto:[email protected]
_________________

Sent to [email protected]

Unsubscribe:
[link removed]

Health Affairs, 1220 19th Street, NW, Suite 800, Washington, DC 20036, United States